Crow's Feet Lines Clinical Trial
Official title:
A Randomized, Double-blind, Active Drug Controlled, Multi-center, Phase Ⅰ/Ⅲ Study to Determine the Efficacy and Safety of Meditoxin® in Treatment of Crow's Feet Line
Verified date | March 2019 |
Source | Medy-Tox |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
to determine the efficacy and safety of Meditoxin® in treatment of crow's feet line
Status | Completed |
Enrollment | 250 |
Est. completion date | May 14, 2018 |
Est. primary completion date | December 1, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Male or female of at least 20 to 65 years old - Bilaterally symmetrical moderate-to-severe CFL at maximum smile on the FWS as rated by the investigator Exclusion Criteria: - Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis - Patients with allergy or hypersensitivity to the investigational drugs or their components - Patients who have bleeding tendency or taking anti-coagulant - Female subjects who are pregnant or lactating. Female subjects of childbearing age who have a plan to get pregnant during the study period, or do not use available contraceptive methods (Women of childbearing age should have negative urine pregnancy test results at baseline visit (0 week) prior to the first injection.) - Patients who are participating in other clinical trials or have participated in other clinical trials 30 days before screening - Patients who are unable to communicate or follow the instructions - Patients who are not eligible for this study based on the judgment of an investigator |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Seoul National University Bundang Hospital | Gyeonggi-do |
Lead Sponsor | Collaborator |
---|---|
Medy-Tox |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants Achieving None or Mild on the Investigator's Assessment of the Severity of Crow's Feet Lines (CFL) at Maximum Smile Using the Facial Wrinkle Scale(FWS) | The Investigator assessed the severity of the patient's Crow's Feet lines at maximum smile using the 4-point Facial Wrinkle Scale where 0=none, 1=mild, 2=moderate or 3=severe. The percentage of participants with a score of none or mild at Day 30 is reported. | 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02248844 -
Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea
|
||
Completed |
NCT02195687 -
BOTOX® in the Treatment of Crow's Feet Lines in China
|
Phase 3 | |
Completed |
NCT01189760 -
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
|
Phase 3 | |
Completed |
NCT01189747 -
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines
|
Phase 3 | |
Recruiting |
NCT04081402 -
A Phase 1/3 Clinical Trial to Evaluate the Safety and Efficacy of HUTOX Compared to Botox® in Subjects With Moderate to Severe Crow's Feet Lines
|
Phase 3 | |
Completed |
NCT01224015 -
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
|
Phase 3 | |
Completed |
NCT02176356 -
Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)
|
Phase 4 | |
Not yet recruiting |
NCT06402058 -
A Study Comparing DMSB01 and Rejuran® for Temporary Crow's Feet Lines Improvement
|
N/A | |
Completed |
NCT06376838 -
To Prove the Non-inferiority of DLMR01 by Evaluating the Injecting Efficacy and Safety DLMR01 and Control for Patients in Crow's Feet
|
N/A | |
Not yet recruiting |
NCT03184363 -
Efficacy and Safety of DWP450 for Treating Crows Feet Lines(CFL) in Combination With Glabellar Lines(Extension Study)
|
Phase 3 | |
Completed |
NCT01797081 -
BOTOX® in the Treatment of Crow's Feet Lines in Japan
|
Phase 3 | |
Completed |
NCT03408236 -
Evaluate the Safety and Efficacy of Botulax® as Compared to Botox® in Subject With Moderate to Severe Crow's Feet Lines
|
Phase 3 | |
Completed |
NCT01797094 -
BOTOX® in the Treatment of Upper Facial Lines in Japan
|
Phase 3 |